Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

Author： Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.3, 2005-06, pp. : 263-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

By Doebele Robert C.   Spigel David   Tehfe Mustapha   Thomas Sachdev   Reck Martin   Verma Sunil   Eakle Janice   Bustin Frederique   Goldschmidt Jerome   Cao Dachuang   Alexandris Ekaterine   Yurasov Sergey   Camidge D. Ross   Bonomi Philip  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 883-892

Blackwell Publishing

Access to resources Recommend Favorite

Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

By Nagel Sylke   Califano Raffaele   Thatcher Nicholas   Blackhall Fiona  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 18, 2007-12 ,pp. : 3265-3275

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

By Esteban Emilio   Fra Joaquin   Fernández Yolanda   Corral Norberto   Vieitez José   Palacio Isabel   Sande José   Fernández José   Muñiz Isabel   Villanueva Noemi   Estrada Enrique   Mareque Beatriz   Uña Esther   Buesa José   Lacave Angel  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 241-248

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

By Reckamp Karen L.   Koczywas Marianna   Cristea Mihaela C.   Dowell Jonathan E.   Wang He-Jing   Gardner Brian K.   Milne Ginger L.   Figlin Robert A.   Fishbein Michael C.   Elashoff Robert M.   Dubinett Steven M.  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

Blackwell Publishing

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite